Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET

BACKGROUND: Primary and secondary drug resistance to imatinib and sunitinib in patients with gastrointestinal stromal tumors (GISTs) has led to a pressing need for new therapeutic strategies such as drug combinations. Most GISTs are caused by mutations in the KIT receptor, leading to upregulated KIT...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Główni autorzy: Pantaleo, Maria Abbondanza, Nicoletti, Giordano, Nanni, Cristina, Gnocchi, Chiara, Landuzzi, Lorena, Quarta, Carmelo, Boschi, Stefano, Nannini, Margherita, Di Battista, Monica, Castellucci, Paolo, Fanti, Stefano, Lollini, Pier Luigi, Bellan, Elena, Castelli, Mauro, Rubello, Domenico, Biasco, Guido
Format: Artigo
Język:Inglês
Wydane: BioMed Central 2010
Hasła przedmiotowe:
Research
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3022678/
https://ncbi.nlm.nih.gov/pubmed/21192792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-9966-29-173
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy